Safety of PERC Tool Validated for Very Low Risk PE Rule Out in ER

Share this content:
Safety of PERC Tool Validated for Very Low Risk PE Rule Out in ER
Safety of PERC Tool Validated for Very Low Risk PE Rule Out in ER

WEDNESDAY, Feb. 14, 2018 (HealthDay News) -- For low risk patients with suspected pulmonary embolism (PE), randomization to eight-item PE rule-out criteria (PERC) seems safe, according to a study published in the Feb. 13 issue of the Journal of the American Medical Association.

Yonathan Freund, M.D., Ph.D., from the Sorbonne Université in Paris, and colleagues conducted a non-inferiority trial in 14 emergency departments in France to validate the safety of PERC-based strategy to rule out PE. A total of 1,916 patients were cluster-randomized: 962 were assigned to the PERC group and 954 to the control group.

The researchers found that a PE was diagnosed at initial presentation in 2.7 percent of patients in the control group, compared with 1.5 percent in the PERC group (difference, 1.3 percent; 95 percent confidence interval, −0.1 to 2.7 percent; P = 0.052). During follow-up, one PE was diagnosed in the PERC group versus none in the control group (difference, 0.1 percent; 95 percent confidence interval, −∞ to 0.8 percent). In the PERC versus the control group, the proportion of patients undergoing computed tomographic pulmonary angiography was 13 versus 23 percent (difference, −10 percent; 95 percent confidence interval, −13 to −6 percent; P < 0.001). Rates were significantly reduced in the PERC group for the median length of emergency department stay and hospital admission.

"These findings support the safety of PERC for very low risk patients presenting to the emergency department," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

NIH Panel Will No Longer Review Gene Therapy Experiments

NIH Panel Will No Longer Review Gene Therapy ...

FDA will now assess gene therapy experiments and products as it does with other treatments, drugs

Doctors Remove Contact Lens Embedded in Eyelid for Years

Doctors Remove Contact Lens Embedded in Eyelid for ...

Lens was encapsulated within the upper eyelid soft tissue since childhood eye trauma

CDC: Brucellosis in Dogs Remains a Public Health Risk

CDC: Brucellosis in Dogs Remains a Public Health ...

Infection is under-recognized, may remain a threat without stronger intervention measures

is free, fast, and customized just for you!




Already a member?

Sign In Now »